Medical specialty – Rhinoplasty Digest http://rhinoplastydigest.com/ Wed, 29 Jun 2022 13:55:04 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://rhinoplastydigest.com/wp-content/uploads/2021/07/icon-2021-07-08T154233.528.png Medical specialty – Rhinoplasty Digest http://rhinoplastydigest.com/ 32 32 Gene Editing Market: Extensive Use of Genome Editing in Personalized Medicine | 360 Research Report https://rhinoplastydigest.com/gene-editing-market-extensive-use-of-genome-editing-in-personalized-medicine-360-research-report/ Wed, 29 Jun 2022 12:58:00 +0000 https://rhinoplastydigest.com/gene-editing-market-extensive-use-of-genome-editing-in-personalized-medicine-360-research-report/ Emerging research logo The growth of the market is attributed to increase in government initiatives in major countries coupled with expanding application areas of genomics The Gene Editing Market Size is Expected to Reach $15.79 Billion by 2027” — Emerging research VANCOUER, BC, CANADA, June 29, 2022 /EINPresswire.com/ — The Global gene editing market is […]]]>

Emerging research logo

The growth of the market is attributed to increase in government initiatives in major countries coupled with expanding application areas of genomics

The Gene Editing Market Size is Expected to Reach $15.79 Billion by 2027”

— Emerging research

VANCOUER, BC, CANADA, June 29, 2022 /EINPresswire.com/ — The Global gene editing market is expected to reach $15.79 billion by 2027, according to a recent report by Emergen Research. The use of technology for the elimination of disease through the direct correction of disturbances in traditional physiology, the engineering of the immunological response and the modification of microorganism targets within the host, which should stimulate the market with substantial opportunities.

The latest report includes extensive coverage of the significant impact of the COVID-19 pandemic on the Gene Editing Company industry. The coronavirus outbreak has had a huge impact on the global economic landscape and, consequently, on this particular business vertical. Hence, the report provides the reader with a clear concept of the current scenario of this business vertical, estimating its COVID-19 aftereffects.

Request a sample PDF copy of the report @ https://www.emergenresearch.com/request-sample/132

Table of Contents Highlights:

Presentation of the report
1.1 Scope of research

1.2 Key Segments of the Gene Editing Market

1.3 Targeting Players

1.4 Market Analysis by Type

1.5 Market Analysis by Application

1.6 Main learning objectives

1.7 Report schedule

Global Growth Trends
2.1 Global Gene Editing Market Size

2.2 Latest Gene Editing Market Trends by Region

2.3 Key business trends

Gene Editing Market Shares of Key Players
3.1 Global Gene Editing Size by Manufacturers

3.2 Key Players in the Global Gene Editing Market

3.3 Key Players Products/Solutions/Services

3.4 New Entrants in the Gene Editing Market

3.5 Mergers, acquisitions, joint ventures and expansion plans

Gene Editing Market by Product Segmentation
4.1 Global Gene Editing Sales by Product

4.2 Global Gene Editing by Product Revenue

Get the Latest Gene Editing Market Report at a Deeply Discounted Rate @ https://www.emergenresearch.com/request-discount/132

Geographic scenario:

In this section of the report, market analysts have provided valuable insights into the geographical segmentation of the gene editing market. They have further estimated current and future market valuations based on supply and demand dynamics and price structure of major regional segments. Moreover, the growth prospects of each regional segment have been meticulously discussed in detail in the report.

The global gene editing market is classified into the following regions:

North America (USA, Canada)
Latin America (Chile, Brazil, Argentina, Rest of Latin America)
Europe (UK, Italy, Germany, France, Rest of EU)
Asia-Pacific (India, Japan, China, South Korea, Australia, rest of APAC)
The Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa, Rest of MEA)
Competitive field:

The global gene editing market is highly consolidated owing to the presence of numerous companies operating in this industry. The report describes these companies’ current market position, past performance, supply and demand graphs, production and consumption patterns, sales network, distribution channels and growth opportunities. on the market. The main market competitors listed in the report are:

Major participants include Cibus, Recombinetics, Inc, Merck KGaA, Sangamo, Accuracy Biosciences and Editas Drugs, among others.

Some highlights of the report

CRISPR accounted for the largest market share due to a wide variety of benefits such as the convenience of tailored choice specific to patient mutations for disease like CF, government initiatives for drug event, devices and vaccines, and investment by market players. for example, in October 2017, Thermo Fisher Scientific and Synthego collaborated to manufacture and distribute an artificial guide polymer product for engineering CRISPR controls. moreover, CRISPR is simple to use, works with high efficiency and reasonable technology.
Recent developments in command writing technologies have resulted in the creation of next-generation nucleases that have higher levels of precision once mutations and genetic defects are corrected. The categories under the order of writing technologies are the four main families of nucleases: ZFN, TALEN, CRISPR/Cas9 and meganucleases.
In June 2019, Vertex Pharmaceuticals acquired Exonics Therapeutics to expand the medical specialty into gene editing. Exonics has its SingleCut CRISPR sequence technology to develop treatments by repairing the mutations that cause different fascicle genetic diseases with significant unmet desires. Thus, the acquisition helped Vertex to develop new treatments for rare diseases.

For the purposes of this report, Emergen Research has segmented the global gene editing market on the basis of technology, end-user, applications, and region:

Technology Outlook (Revenue, USD Billion; 2017-2027)

(CRISPR)/Cas9
TALENS/MegaTALs
ZFN
ANTISENSE
Other technologies
Application Outlook (Revenue, USD Billion; 2017-2027)

Cell line engineering
animal genetic engineering
plant genetic engineering
Diagnostic applications
Drug discovery and development
End User Outlook (Revenue, USD Billion; 2017-2027)

Biotechnology and pharmaceutical companies
University and government research institutes
Contract Research Organizations (CROs)

Request a custom sample report @ https://www.emergenresearch.com/request-for-customization/132

Thank you for reading our report. To learn more about the report or to inquire about customizing it, please contact us. We will offer you a report that is well suited to your requirements.

Read the latest articles published by Emergen Research:

https://www.emergenresearch.com/industry-report/plant-based-food-and-beverages-alternatives-market

https://www.emergenresearch.com/industry-report/fermented-food-and-ingredients-market

https://www.emergenresearch.com/industry-report/rapid-liquid-printing-market

https://www.emergenresearch.com/industry-report/biorational-product-market

https://www.emergenresearch.com/industry-report/smart-product-vending-machines-market

About Emergen Research

Emergen Research is a market research and consulting firm that provides syndicated research reports, custom research reports, and consulting services. Our solutions are uniquely focused on your goal of locating, targeting and analyzing changes in consumer behavior across demographics, across industries, and helping customers make smarter business decisions. We offer market intelligence research ensuring relevant and factual research across multiple sectors including health, touchpoints, chemicals, types and energy. We are constantly updating our search offerings to ensure that our clients are aware of the latest trends existing in the market. Emergen Research has a strong base of experienced analysts from a variety of areas of expertise. Our industry experience and ability to develop a workable solution to any research problem gives our clients the ability to secure an edge over their respective competitors.

Press release available @ https://www.emergenresearch.com/press-release/global-gene-editing-market

Eric Lee
Emerging research
+91 90210 91709
sales@emergenresearch.com
Visit us on social media:
Facebook
Twitter
LinkedIn

The global gene editing market is expected to reach $15.79 billion by 2027, according to a recent report by Emergen Research.

]]>
The Italfarmaco group announces the first positive data from the phase 3 trial showing the beneficial effect of givinostat in patients with Duchenne muscular dystrophy https://rhinoplastydigest.com/the-italfarmaco-group-announces-the-first-positive-data-from-the-phase-3-trial-showing-the-beneficial-effect-of-givinostat-in-patients-with-duchenne-muscular-dystrophy/ Sun, 26 Jun 2022 01:03:15 +0000 https://rhinoplastydigest.com/the-italfarmaco-group-announces-the-first-positive-data-from-the-phase-3-trial-showing-the-beneficial-effect-of-givinostat-in-patients-with-duchenne-muscular-dystrophy/ — Study Meets Primary Endpoint, Secondary and Exploratory Endpoints Showing Consistency with Primary Endpoint — — The data reinforce the safety profile previously observed for Givinostat; treatment in boys with DMD continues to show good safety profile — — The Company Plans to Discuss the Possibility of Submitting a Marketing Application to Regulatory Authorities for […]]]>

— Study Meets Primary Endpoint, Secondary and Exploratory Endpoints Showing Consistency with Primary Endpoint —

— The data reinforce the safety profile previously observed for Givinostat; treatment in boys with DMD continues to show good safety profile —

— The Company Plans to Discuss the Possibility of Submitting a Marketing Application to Regulatory Authorities for Givinostat in DMD —

— The results were presented at the PPMD ​​annual conference on June 25, 2022 —

MILAN, June 26, 2022–(BUSINESS WIRE)–Italfarmaco Group today announced positive early data from its completed Phase 3 EPIDYS trial with Givinostat, the company’s proprietary histone deacetylase (HDAC) inhibitor, in boys with Duchenne muscular dystrophy (DMD). The primary objective of the study was to assess the effects of Givinostat on slowing disease progression in ambulatory DMD boys aged 6 years and older on chronic steroids. The study compared Givinostat to placebo and achieved the primary endpoint (change from baseline in time to climb 4 steps) after 18 months of treatment in the target population1 with key secondary endpoints consistent with the functional primary endpoint. Givinostat continued to demonstrate a safety profile consistent with previous studies. The main data was presented by the Chief Medical Officer of the Italfarmaco Group, Dr. Paolo Bettica, on June 25, 2022, during the hybrid Parent Project on Muscular Dystrophy (PPMD) Annual Conference.

In October 2020, the United States Food and Drug Administration (FDA) granted Givinostat Rare Pediatric Disease Designation for the treatment of DMD. Previously, the company also received orphan drug designation from the FDA and EMA, and Fast Track designation from the FDA. Based on the study results, which show that adding Givinostat to steroid therapy results in clinical benefits for study participants, the Company plans to meet with U.S. and European regulators to discuss the opportunity to submit a marketing application and solicit comments on a future submission of regulatory approval application. The company intends to submit the full results of the EPIDYS study for publication in a peer-reviewed journal in due course.

“These early Phase 3 results in DMD add to the growing dataset we have collected over the past several years that have shown positive results with our investigational therapeutic candidate, Givinostat, when taken with steroids in patients with DMD, offering new hope to boys with DMD. , their families and the medical community,” said Paolo Bettica, MD, PhD, Italfarmaco Group Chief Medical Officer. “There is a huge unmet medical need for additional drugs to treat this debilitating rare disease and with these positive results, we intend to meet with regulatory agencies to share these findings and discuss a way forward to submit the ‘full dataset in a marketing application for a potential We are extremely excited to share these positive new insights from the EPIDYS trial with the community and would like to thank all stakeholders involved.’

The EPIDYS Phase 3 clinical trial is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Givinostat in people with DMD (Cinicaltrials.gov: NCT02851797). The trial recruited 179 ambulant males with an average age of 9 and on stable steroids for at least 6 months. The boys were randomized 2:1 and chronically treated with Givinostat oral suspension or placebo for an 18-month period. Among them, 120 boys formed the target population1.

Overview of clinical results
Main criterion: The mean change from baseline to climbing 4 steps was selected as the primary endpoint to assess the efficacy of Givinostat compared to placebo. The results demonstrated a slower decline in the performance of this functional task in the group treated with Givinostat (difference vs. placebo of 1.78 seconds, p=0.0345).

Key Secondary Endpoints: Various secondary endpoints were analyzed and showed results consistent with the primary functional endpoint. These included functional tests such as the North Star Ambulatory Assessment (NSAA) and the Time to Rise Test (TTR) as well as muscle strength analyses. Fat infiltration into the vastus lateralis (VL) muscle of the thigh is a hallmark of disease progression in patients with DMD and has been measured using a noninvasive objective imaging method called magnetic resonance spectroscopy (MRS) to assess the effectiveness of Givinostat. The data indicated that treatment with Givinostat delayed fat infiltration by approximately 30% (difference vs placebo, -2.9%, nominal p=0.035). Additional exploratory endpoints were also analyzed in the clinical study. These results further confirm the potential of Givinostat as a clinical benefit for boys with DMD.

Security and tolerance: The majority of adverse events (AEs) were mild to moderate in intensity (95%). Three boys (2.5%) treated with Givinostat withdrew from the trial due to an AE. Similar to previously observed adverse reactions occurring in at least 1 in 10 subjects were diarrhea, abdominal pain, thrombocytopenia, hypertriglyceridemia, decrease in platelets and increase in triglycerides. Givinostat tolerance was managed with appropriate monitoring and dose adjustments. No other security issues were observed.

Professor Eugenio Mercuri, Professor of Pediatric Neurology at the Catholic University of Rome, Italy, commented: “These results show the beneficial effect of Givinostat in boys with DMD, proving its ability to slow disease progression.”

“I believe the results of the EPIDYS study are clinically meaningful, are consistent with previous findings, and further demonstrate that givinostat can slow muscle deterioration, leading to a reduction in muscle function decline,” added Teacher. Craig McDonald, professor in the Department of Pediatrics and Physical Medicine and Rehabilitation at the University of California, Davis.

About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a serious genetic neuromuscular disease characterized by progressive muscle weakness and degeneration and is the most common type of muscular dystrophy in the world. DMD is caused by mutations in the DMD gene that result in the absence of a functional dystrophin protein, which plays a crucial role in maintaining the structural and membrane stability of muscle fibers. The disease primarily affects boys with symptoms usually seen between the ages of two and five that worsen over time with individuals losing their ability to walk. Eventually, the heart and respiratory muscles are affected, leading to premature death. The incidence of DMD is approximately 1 in 3500 to 6000 male births worldwide.

About Givinostat
Givinostat is an investigational drug discovered through internal research and development efforts of Italfarmaco Group in collaboration with Lorenzo Puri (Sanford Burnham Prebys Medical Research Institute, San Diego, formerly Santa Lucia Foundation, Rome) and his team, and partnerships with Telethon and Parent Project aps. Its safety and efficacy are being evaluated for the treatment of Duchenne and Becker muscular dystrophy. Givinostat inhibits histone deacetylases (HDACs). HDACs are enzymes that prevent gene translation by altering the three-dimensional folding of DNA in the cell. Studies show that higher than normal HDAC activity in people with DMD can prevent muscle regeneration and also trigger inflammation. In the company’s DMD clinical study, in boys aged 7 to less than 11 years, Givinostat was observed to slow the progression of the disease, significantly increase muscle mass and reduce the amount of fibrotic tissue . In this study, treatment with Givinostat also significantly reduced muscle tissue necrosis and fat replacement, two additional endpoints related to disease progression (Bettica et al., Neuromuscular Disorders 2016).

About Italfarmaco Group
Italfarmaco Group is a specialty pharmaceutical company engaged in the discovery, development, manufacture and marketing of branded prescription and over-the-counter products in more than 60 countries on 5 continents. Italfarmaco Group’s research and development expertise is best demonstrated by its HDAC inhibitor development programs, addressing new therapeutic treatments for specialized and rare diseases. Through both marketed drugs and compounds in development, Italfarmaco Group is dedicated to serving patients whose needs remain largely unmet.

1 Target population: Individuals with a Vast External Muscle Fat Fraction (VL MFF) assessed by Magnetic Resonance Spectroscopy (MRS) in the range >5% and ≤30%

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220625005001/en/

contacts

For media inquiries:
Trophic communication
Jacob Verghese, PhD or Laura Mittmann, PhD
+49 (0) 89 2070 89831 or +49 (0) 151 5798 4222
italfarmaco@trophic.eu

]]>
American College of Physicians Pushes Payment Reforms to Increase Value and Equity https://rhinoplastydigest.com/american-college-of-physicians-pushes-payment-reforms-to-increase-value-and-equity/ Fri, 24 Jun 2022 13:29:41 +0000 https://rhinoplastydigest.com/american-college-of-physicians-pushes-payment-reforms-to-increase-value-and-equity/ The company of internal medicine specialists urges to redouble its efforts to shift from volume-based physician payment to value-based payment models. The American College of Physicians (ACP) offered a seven-part program series of reforms link physician compensation to value and equity rather than volume of services. Since the passage of the Patient Protection and Affordable […]]]>

The company of internal medicine specialists urges to redouble its efforts to shift from volume-based physician payment to value-based payment models.

The American College of Physicians (ACP) offered a seven-part program series of reforms link physician compensation to value and equity rather than volume of services.

Since the passage of the Patient Protection and Affordable Care Act in 2010, policymakers and legislators have sought to replace fee-for-service reimbursement in health care with value-based payment models. Despite more than a decade of effort, a recent study found that physician compensation is still largely based on the volume of services rather than the value of services.

The ACP is made up of specialists and sub-specialists in internal medicine. With more than 160,000 members in several countries, the CPA is the largest medical specialty society in the world.

This week, the CPA released the organization’s seven-part set of reforms on paying doctors in a stand in Annals of Internal Medicine. Physician payment models dominated by fee-for-service approaches do not promote value or equity in health care in the United States, the position paper states. “Socioeconomic factors remain one of the most clinically significant contributors to health outcomes in this country, but the current fee-for-service structure encourages volume and fails to account for these factors. ‘American College of Physicians offers specific policy recommendations on reforming payment programs, including those designed to address underserved patient populations, to better address the value of health care and achieve greater equity.’

The position paper says there is a need to design “smarter” healthcare payment models. “The approach of building a health system that is smarter about how dollars are spent to improve people’s health must shift to one with a clear intent to reduce health inequities and tackle social drivers of health.”

The position paper calls for more meaningful efforts to create value-based payment models. “Political leaders and the clinical community must work together to move towards equity using value-based payment. For more than a decade, policy goals have emphasized the need to achieve greater equity, but the the fact remains that the execution of these policies continues to lag. Now is the time to set a national intent to build on this experience and support the implementation and evaluation of payment approaches to advance the health equity and overcoming social factors and other disparities that lead to poorer health outcomes.

post one

The CPA is calling on Medicare and other payers to develop prospective, population-based payment models for primary and comprehensive care. These payment models should support access to care and address health care disparities and inequities related to personal characteristics and/or social drivers of health. New payment models should be designed to improve care for underserved patient populations.

position two

Research should be conducted to measure the cost of caring for patients who are impacted by health care disparities and inequities based on personal characteristics and/or social drivers of health. In value-based payment models, performance and cost measures must be adjusted for risk, health status, and social factors of health. Performance and cost data should be used to improve the value of primary and comprehensive care.

position three

The Health Insurance Act should be amended to establish a means of calculating savings resulting from increased investments and payments for primary care and preventive health care services (Part B) that reduce visits to emergencies and hospitalizations (part A). These savings should be reinvested in primary and preventive care as well as social and public health services. Investment in primary care should not be based solely on short-term savings, as primary care improves the health of the population and some savings are realized over several years.

position four

The Federal Secretary of Health and Human Services should reform Medicare Quality Payment Program to ensure that the program addresses inequities, health care disparities and social drivers of health. New financial policies and approaches should encourage medical practices to adopt value-based payment models.

fifth position

Delivery and payment systems should help clinicians and health facilities deliver care to patients when and where they need it in a range of modalities, including in-person visits and telehealth. This approach to care is particularly important for patients struggling with health care disparities and inequities based on personal characteristics and/or social drivers of health. These delivery and payment systems should not increase the administrative burden on clinicians or inappropriately challenge clinicians’ judgment.

Sixth position

Funds should be allocated to the development of health information technology systems and communication capabilities such as broadband so that delivery and payment reforms meet the needs of all patient populations. These capabilities should help patients who experience health care disparities and inequities related to personal characteristics and/or social drivers of health. Policies promoting these capabilities should not unintentionally redistribute resources from at-risk patients or create incentives to avoid at-risk patients.

Position seven

Health actors, including policymakers, payers, health systems, private sector investors and philanthropic organizations, should develop funding mechanisms other than direct payment to clinicians, such as grants to remedy inequalities, health care disparities and social drivers of health.

Related: Value-based care is making progress, but the transition is proving difficult

Christopher Cheney is the Clinical Care Editor at HealthLeaders.

]]>
Bruce Nuclear is set to produce a new radioactive isotope for the treatment of cancer https://rhinoplastydigest.com/bruce-nuclear-is-set-to-produce-a-new-radioactive-isotope-for-the-treatment-of-cancer/ Tue, 21 Jun 2022 22:43:43 +0000 https://rhinoplastydigest.com/bruce-nuclear-is-set-to-produce-a-new-radioactive-isotope-for-the-treatment-of-cancer/ Breadcrumb Links Local News The operator of the Bruce Nuclear Generating Station, one of the largest nuclear power plants in the world, is producing a new medical isotope and accelerating production of the radioactive substance for the global market. Bruce Power says it is closer to producing the medical isotope Lutetium-177, which is used to […]]]>

The operator of the Bruce Nuclear Generating Station, one of the largest nuclear power plants in the world, is producing a new medical isotope and accelerating production of the radioactive substance for the global market.

Content of the article

The operator of the Bruce Nuclear Generating Station, one of the largest nuclear power plants in the world, is producing a new medical isotope and accelerating production of the radioactive substance for the global market.

Advertisement 2

Content of the article

Kincardine’s Bruce Power, with support from two international partners, has produced lutetium-177 in one of its nuclear reactors, a first step towards commercial production of the versatile cancer-fighting isotope.

In a statement Tuesday, Bruce Power executive vice president of operations James Scongack said the new medical isotope is the result of years of hard work by hundreds of people.

“We are proud to demonstrate the power of Bruce Power’s CANDU reactors to deliver reliable, large-scale production of critical medical isotopes for use in the fight against cancer,” Scongack said in a press release.

Lutetium-177 treatments, which target malignant cells while leaving surrounding healthy tissue alone, are being used on a growing number of cancers, including prostate cancer and neuroendocrine tumors, cancer that grows in the nervous system and body hormones.

Advertisement 3

Content of the article

Lutetium-177 production has been on Bruce Power’s radar for several years. In 2020, the energy producer has set 2022 as its production target for the isotope, pending regulatory approval.

Bruce Power has partnered with Isogen and ITM Isotope Technologies Munich on the latter venture.

Lutetium-177 was created using the plant’s new isotope production system, equipment installed in unit seven of the plant during recent scheduled maintenance.

Bruce Power’s newest isotope was created by irradiating ytterbium-176, a non-radioactive isotope. The isotopes were sent to Germany for processing.

Bruce Power will commission and upgrade its isotope production system this summer. Commercial production of lutetium-177 will come soon after, pending final approval from the Canadian Nuclear Safety Commission.

Advertisement 4

Content of the article

Isotopes are atoms that have the same number of protons in their nucleus as their base element, but a different number of neutrons. Unstable isotopes decompose by emitting radiation.

Some of these unstable isotopes play a key role in nuclear medicine, a medical specialty that uses radioactive substances to treat, study or diagnose disease.

Medical isotopes can be produced in nuclear reactors, such as that at Bruce Power, and particle accelerators found in major medical research centers and hospitals, including the Lawson Health Research Institute in London.

Lutetium-177 is the latest medical isotope produced by the Kincardine nuclear power facility.

Bruce Nuclear already produces cobalt-60, a medical isotope used to treat brain and breast cancer.  (Provided/Power Bruce)
Bruce Nuclear already produces cobalt-60, a medical isotope used to treat brain and breast cancer. (Provided/Power Bruce)

In partnership with an Ottawa company, Bruce Power produces cobalt-60, a medical isotope used to sterilize medical equipment – including single-use swabs used to test for COVID-19 – and treat brain tumors and breast cancer.

The plant harvested its first medical-grade Cobalt-60 in March 2019.

In 2020, Bruce Power assembled an advisory board to guide the development of its medical isotopes division.

jbieman@postmedia.com

Twitter.com/JenatLFPress

Advertising

Advertisement 1

comments

Postmedia is committed to maintaining a lively yet civil discussion forum and encourages all readers to share their views on our articles. Comments can take up to an hour to be moderated before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications. You will now receive an email if you receive a reply to your comment, if there is an update to a comment thread you follow, or if a user follows you comments. Visit our Community Rules for more information and details on how to adjust your E-mail settings.

]]>
Is the health system an electoral sword of Damocles for work? https://rhinoplastydigest.com/is-the-health-system-an-electoral-sword-of-damocles-for-work/ Sat, 18 Jun 2022 17:00:00 +0000 https://rhinoplastydigest.com/is-the-health-system-an-electoral-sword-of-damocles-for-work/ Ian Powell is Executive Director of the Association of Salaried Medical Specialists (ASMS). OPINION: The legend of the Sword of Damocles – about the imminent and ever-present peril facing those in positions of power – is relevant for voters in the 2023 general election, as they consider the Labor government’s handling of the healthcare system […]]]>

Ian Powell is Executive Director of the Association of Salaried Medical Specialists (ASMS).

OPINION:

The legend of the Sword of Damocles – about the imminent and ever-present peril facing those in positions of power – is relevant for voters in the 2023 general election, as they consider the Labor government’s handling of the healthcare system .

In 2017, the Labor government inherited a health system in crisis, with severe labor shortages.

Although this is a legacy, the government has largely ignored it. Labor shortages now vary between ⅕ to ¼ depending on occupational group. Even before the pandemic, these shortages had serious implications for access to planned surgery and other treatments, overcrowded emergency departments, availability of hospital beds, and compromised ability to diagnose patients in time. clinically appropriate.

READ MORE:
* DHB boss: Southland decisions should be based on need, not budget
* Rural specialized health services in crisis
* Cancer Control boss Diana Sarfati will succeed Ashley Bloomfield as acting chief health officer

Covid-19 accelerated this, but did not cause it.

The government’s response was obviously pathetic. In 2018, he trumpeted the formation of a committee; in fact, it was a reconstituted committee with less authority than its predecessor.

The government’s only responsiveness was to nurses, who make up the bulk of the DHB workforce. But that was only due to persistent militant industrial action by the nurses, and the dispute remains unresolved.

Public hospitals are heavily dependent on the recruitment of specialist doctors from abroad. Aotearoa New Zealand is one of the OECD countries most dependent on recruitment from abroad.

We are in fierce competition with Australia. But, while the overall salary gap between Australia and New Zealand favors the former by around 20-30%, for specialists the gap is over 60%.

So why the political negligence? The government has made a conscious political call to ignore pressures on the health system and focus instead on restructuring based on the advice of business consultants.

The statutory bodies responsible for delivering community and hospital-based health care to geographically defined populations (DHBs) are to be abolished and replaced on July 1 by a new, additional national monolith: Health New Zealand (HNZ).

Restructuring rarely succeeds in achieving lasting improvements. But the government has instead listened to the external consultants who, unsurprisingly, are the biggest beneficiaries of this restructuring.

Health facilities were not the cause of the workforce crisis, nor is restructuring (or part of) the solution. It’s an ABC of health systems, but one the government has failed to grasp.

Not only has this restructuring distracted the government from addressing the real crisis, but its rushed nature has meant that the new HNZ is ill-equipped to hit the road.

Ian Powell has criticized the government's decision to abolish the DHBs, saying devolving decision-making to bureaucrats in Wellington could have implications for the unique needs of populations - such as those in South Auckland.

Provided

Ian Powell has criticized the government’s decision to abolish the DHBs, saying devolving decision-making to bureaucrats in Wellington could have implications for the unique needs of populations – such as those in South Auckland.

HNZ will start with most leaders including interim appointments. These are largely those who currently hold leadership positions in DHB. Ironically, the Minister of Health has scapegoated DHBs for the problems in the healthcare system.

The “tempors” are capable people who will do their best, but they will keep the system going rather than responding to the pressures caused by this labor crisis. This means that there will be a leadership vacuum for some time. Consequently, the labor crisis will worsen.

At the start of 2020, National and Labor were neck and neck in the polls. The National had clawed back a clear Labor lead that had been rightly earned by Prime Minister Jacinda Ardern’s impressive leadership in response to the deadly mosque attacks a year earlier.

The government’s (at the time) impressive and high-profile response to the pandemic led to a complete reversal of the electoral odds seven months later

Labour’s strong polls continued until the end of September, it still handled the pandemic response well.

Subsequently, the wheels crumbled as he resorted to spin rather than scientific evidence to justify his evolution from the laissez-faire response. To top it off, National elected a capable and confident new leader.

Right now, the polls show National a bit ahead. This is largely because Labor has lost its favorable point of difference with National on the response to the pandemic and is not strong on the implementation of various issues including the healthcare system.

Health is an important election issue because of its far-reaching impact on so many New Zealanders. In the 2017 elections, health was detrimental to the national government. Since then, the labor crisis has only gotten worse.

There’s no way ‘Team Interim’ (aka Health NZ) will reverse this crisis, so it’s making a tangible difference in access to healthcare ahead of the next election.

But what made it even worse was the most incompetent decision I’ve seen a government take on health – in the midst of a pandemic, to dismantle the system of supply and delivery of health care in communities and hospitals and replace it with an untested alternative which, for a while at least, will have interim leadership.

At the time of the next election, the government will not be able to blame the labor crisis on the DHBs or the previous government. Labor tends in the polls to be under the sword of Damocles. It will certainly be below at election time.

What do you think? Email sundayletters@stuff.co.nz

]]>
Children’s of Alabama tied for best children’s hospital in the Southeast Division by US World News Report https://rhinoplastydigest.com/childrens-of-alabama-tied-for-best-childrens-hospital-in-the-southeast-division-by-us-world-news-report/ Tue, 14 Jun 2022 18:11:00 +0000 https://rhinoplastydigest.com/childrens-of-alabama-tied-for-best-childrens-hospital-in-the-southeast-division-by-us-world-news-report/ BIRMINGHAM, Ala. (WBRC) – Children’s of Alabama is tied for the best children’s hospital in the Southeast Division by a US World News Report. “The annual US News Best Children’s Hospitals The rankings, now in their 16th year, offer guidance for parents looking for the best place for their very sick child. The top 50 […]]]>

BIRMINGHAM, Ala. (WBRC) – Children’s of Alabama is tied for the best children’s hospital in the Southeast Division by a US World News Report.

“The annual US News Best Children’s Hospitals The rankings, now in their 16th year, offer guidance for parents looking for the best place for their very sick child. The top 50 medical centers are classified into 10 specialties, including pediatric cancer, pediatric cardiology and heart surgery and pediatric orthopedics. In the 2022-2023 ranking, 90 hospitals ranked among the best in at least one pediatric medical specialty. Ten of these hospitals have earned a spot on America’s Best Children’s Hospitals Honor Roll by earning points for ranking well in many specialties,” US World News said in the report.

Regional rankings

To help families identify high-quality pediatric centers near them, US News also ranked children’s hospitals in each state and seven multi-state regions. The multi-state regions and the #1 hospital in each region are:

You can view the full report on this link.

CLICK HERE TO GET THE WBRC FOX6 NEWS APP

Subscribe to our WBRC newsletter and get the latest local news and weather delivered straight to your email.

Copyright 2022 WBRC. All rights reserved.

]]>
An expert discusses new specialty drugs that are in the pipeline https://rhinoplastydigest.com/an-expert-discusses-new-specialty-drugs-that-are-in-the-pipeline/ Sun, 12 Jun 2022 23:14:15 +0000 https://rhinoplastydigest.com/an-expert-discusses-new-specialty-drugs-that-are-in-the-pipeline/ In an interview with Pharmacy hours® at the American Society of Health-System Pharmacists Summer Meetings and Expos, Aimee Banks, PharmD, BCPS, MSCS, Clinical Pharmacist at the Multiple Sclerosis Clinic at Vanderbilt University Medical Center, discusses new therapies in hematology, oncology and autoimmune diseases in development that pharmacists need to know about. Q: Are there new […]]]>

In an interview with Pharmacy hours® at the American Society of Health-System Pharmacists Summer Meetings and Expos, Aimee Banks, PharmD, BCPS, MSCS, Clinical Pharmacist at the Multiple Sclerosis Clinic at Vanderbilt University Medical Center, discusses new therapies in hematology, oncology and autoimmune diseases in development that pharmacists need to know about.

Q: Are there new hematology and oncology drugs in the pipeline that pharmacists should keep an eye out for?

Aimee Banks: There are yes, in fact, Sandra Cuellar, PharmD, presented the hematology and oncology pipeline earlier today, and there are several very interesting agents that have a top-notch designation with respect to new mechanisms of action. Just a couple she highlighted on a and the melanoma space is Opdualag. It is a very interesting agent that has just had recent approval, but a great breakthrough in this disease state. Opdualag for melanoma should be noted.

In the area of ​​non-small cell lung cancer, it appears that therapies actually target this specific gene expression. There are many different genetic mutations and it is enough to keep an eye out for the different agents being developed as their mechanisms are tailored very specifically to these genetic mutations and expressions. That’s really what she pointed out in regards to non-small cell lung cancer.

When it comes to breast cancer treatments, Dr. Khullar has really done a great job of discussing oral SERDs, which are very specific to hormone-positive breast cancer treatments. These specific cancers are usually very resistant to the current agent. Agents in this class of SERDs for the treatment of breast cancer are really important to watch out for.

In the multiple myeloma space, she was very excited and passionate about introducing tocilizumab, which is a biospecific antibody that has very robust and specific results in this patient population, especially for patients who have had treatment failures current agents in the market. Lots of growth in oncology and lots of really important agents for pharmacists to watch out for.

Q: What are the new autoimmune therapies in the pipeline that pharmacists should be aware of?

Aimee Banks: In the autoimmune space, Caitlyn Young, PharmD, presented several types of subcategories, but what I take away from her presentation today is that there are a lot of extensions of labels. Therapies that have been on the market and approved for other diagnoses and indications, their labels are updated to include new indications.

It was kind of a takeaway for me from his program.

Then she also talked about biosimilars, not only the newer treatments, but also some older agents, which have even been available for several years now. We’re really on the cusp of having kind of a boom in terms of a significant number of biosimilars in autoimmune diseases that will be on the market, which I think will be positive for patient care because it there will hopefully be more affordable options. It’s going to be very difficult for the specialty pharmacist and the clinical pharmacist, I think, to help with the transition of care as patients move from agent to agent. These are 2 kinds of takeaways from Dr. Young’s presentation.

Then in the area of ​​neurology, which is what I’m most specifically involved in day-to-day patient care in the MS space, I think a key agent to focus on is the next agent we’ll have approved as ublituximab for the treatment of MS. This is not a new mechanism, but it may have some advantages over currently available treatments. It is therefore to be monitored.

Then Bruton’s tyrosine kinase inhibitors, or BTKIs, this class of drugs is still in an early stage of development and research. However, there is really promising data, not only for relapsed patients, but also for patients with progressive disease. So those won’t be approved next year, but in the next 1-2 years I really want to keep an eye out for the results of the phase three data, or rather the phase three clinical trial data, for these BTK inhibitors, hoping that they will really have these positive results for patients with progressive multiple sclerosis.

Then, in other areas of neurology, in particular, ramucirumab has just been approved for generalized myasthenia gravis. It is currently being studied in the neuromyelitis optica spectrum disorder. So hopefully it will be another approved treatment there.

Then in the Alzheimer’s space, several agents that are in earlier development, but definitely want to keep an eye on these. They are moving from phase 2 to phase 3 studies and are already being reviewed by the FDA, even before the phase 3 trials are completed, the FDA could at least review them before the completion of these phase trials 3, which is a bit unique in this space, so those are the ones I’d say keep an eye on the most.

]]>
Four independent studies on Voraxaze® published in the European https://rhinoplastydigest.com/four-independent-studies-on-voraxaze-published-in-the-european/ Thu, 09 Jun 2022 08:49:50 +0000 https://rhinoplastydigest.com/four-independent-studies-on-voraxaze-published-in-the-european/ Vienna, June 09, 2022 (GLOBE NEWSWIRE) — The European Hematology Association (EHA) conference has published four independent studies on Voraxaze® (glucarpidase) by various researchers for inclusion in its June 2022 EHA Hybrid Congress Abstract Book and for publication in HemasphereEHA’s open access journal. The four summaries are the result of independent studies in Europe and […]]]>

Vienna, June 09, 2022 (GLOBE NEWSWIRE) — The European Hematology Association (EHA) conference has published four independent studies on Voraxaze® (glucarpidase) by various researchers for inclusion in its June 2022 EHA Hybrid Congress Abstract Book and for publication in HemasphereEHA’s open access journal.

The four summaries are the result of independent studies in Europe and the United States; three explore whether to regularly give Voraxaze® in combination with high-dose methotrexate (“planned use”) may reduce toxicity, manage risk to patients and help them complete treatment.

  • INTENDED-USE GLUCARPIDASE FOR EXTERNAL ADMINISTRATION OF HIGH-DOSE METHOTREXATE (HD-MTX) IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC, by Lauren Schaff, Mina Lobbous, Dean Carlow, Lisa DeAngelis, Louis Burt Nabors, and Christian Grommes, demonstrates the feasibility of planned use of Voraxaze to facilitate outpatient administration of HD-MTX to patients with CNS lymphoma . Twenty outpatient treatments of HD-MTX with glucarpidase were administered to a total of 7 patients. Some Grade 1 and Grade 2 adverse events attributable or possibly attributable to Voraxaze were noted. None of the patients required hospitalization during treatment. [Link to abstract]
  • REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) DAMAGE WHO RECEIVE HD-MTX: PHASE 2 by Adolfo De La Fuente, Francisco Javier Peñalver, Pilar Herrera, Raul Cordoba, Carmen Martinez Chamorro, Maria Teresa Olave, Isidro Jarque and Mónica Estévez, is a multicenter, open-label, interventional, non-randomized, phase 2 pilot study in patients with lymphoma large B-cells at high risk of CNS relapse to assess the prophylactic effect of glucarpidase in MTX-related toxicity administered after 12 hours of HD-MTX. The study aims to describe the reduction in MTX levels after routine administration of glucarpidase 12 hours after the start of HDMTX infusion in DLBCL patients at high risk of CNS involvement. This trial is not over. [Link to abstract]
  • INTENDED USE OF GLUCARPIDASE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA AND KIDNEY FUNCTION DISORDERS – THE STUDY VALIDATED by Sven Liebig, Susen Burock, Immanuel Merz, Franz Knörnschild, Peggy Kießling, Kai Kappert, Ulrich Keller and Stefan Schwartz evaluates the safety as well as pharmacological efficacy of planned and repeated use of glucarpidase after HD-MTX in patients with CNSL and impaired renal function. Glucarpidase administration resulted in a rapid and pronounced reduction in blood MTX levels (>97%) within 15 minutes and within 12 treatment cycles for four patients, demonstrating that treatment with HD-MTX and glucarpidase is feasible in patients with CNSL and renal failure. [Link to abstract]
  • A POPULATION PHARMACOKINETIC MODEL OF HIGH-DOSE METHOTREXATE IN ADULTS WITH CANCER IDENTIFIES BASAL ALBUMIN, BODY WEIGHT, AND TIME-DEPENDENT CREATININE AS PREDICTORS OF ACUTE KIDNEY INJURY by Scott Howard, Manuel Ibarra, Ryan Combs, and Paula Schaiquevich, describes a population pharmacometric model of HD-MTX clearance developed by the authors that takes into account weight, albumin, and time-dependent creatinine to predict the ARI and guide supportive care in patients with delayed disease. Elimination of HD-MTX. AKI patients who did not receive glucarpidase experienced a significantly longer hospital stay (p<0.01) and methotrexate clearance time (p<0.01). [Link to abstract]

“We are excited to see top researchers working to explore how regular administration of Voraxaze® in combination with methotrexate could improve cancer care for appropriate patients,” said Christon Hill, Group Chief Innovation Officer for SERB and BTG Specialty Pharmaceuticals. “These encouraging early results suggest that such treatment regimens can help manage patient risk and ensure that more patients are able to complete their cancer treatment.”

About Voraxaze® (glucarpidase)

Voraxaz® (glucarpidase) is currently approved in all member states of the European Union as well as in Iceland, Liechtenstein and Norway, where it is designated as an orphan drug.

Voraxaz® is approved by the European Commission to reduce the toxic plasma concentration of methotrexate in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.

Detailed recommendations for the use of Voraxaze ® are described in the Summary of Product Characteristics (SmPC) and in the US Prescribing Information (USPI).

SERB Specialty Pharmaceuticals market Voraxaze® in the European Union. BTG Voraxaze Specialty Pharmaceuticals Market® in the USA. SERB acquired BTG Specialty Pharmaceuticals in March 2021. Glucarpidase is sold in Japan as Megludase® by BTG’s marketing partner, Ohara Pharmaceutical Co.

About SERB and BTG Specialty Pharmaceuticals

Together, SERB and BTG Specialty Pharmaceuticals form a growing specialty pharmaceutical company and a dedicated ally of healthcare providers treating critically ill patients, with a focus on emergency care and rare diseases. For more than 30 years, we have made it possible to treat these complex and life-threatening conditions, supporting clinicians, healthcare systems and governments while offering hope to patients and their families. As a fully integrated company, we have the experience and capabilities to source, develop and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain.

Learn more about SERB: https://serb.eu/

Learn more about BTG Specialty Pharmaceuticals: btgsp.com.

        
]]>
New career opportunities: week of June 7, 2022 https://rhinoplastydigest.com/new-career-opportunities-week-of-june-7-2022/ Tue, 07 Jun 2022 17:42:37 +0000 https://rhinoplastydigest.com/new-career-opportunities-week-of-june-7-2022/ With ACS Surgery Career Connection, you can search over 1,000 surgeon-specific positions and apply for positions that interest you. It is the premier resource for connecting highly qualified surgeons with the best career opportunities across the country. Log in today and find your next career opportunity. You can customize your search to target opportunities that […]]]>

With ACS Surgery Career Connection, you can search over 1,000 surgeon-specific positions and apply for positions that interest you. It is the premier resource for connecting highly qualified surgeons with the best career opportunities across the country. Log in today and find your next career opportunity. You can customize your search to target opportunities that interest you.

Current opportunities include:

Neurosurgeon | Allegheny Health Network, Erie, PA

Allegheny Health Network (AHN) is recruiting a full-time Neurosurgeon to join AHN Saint Vincent in Erie, PA. AHN Saint Vincent, located on the shores of Lake Erie, is a 350-bed tertiary care hospital serving the tri-state area. The Department of Neurosurgery has 23 neurosurgeons and 30 neurologists specializing in a myriad of neurosurgical disorders including brain, spine and skull surgery, stroke, movement disorders, cranial nerve disorders, neuro -oncology, epilepsy, headaches, neuromuscular disorders, dementia, concussions, and more.

Learn more.

Colorectal surgeon | Corporate Medical Recruitment, Canton, OH

Enterprise Medical Services, a leading recruitment and consulting firm for physicians, executives and mid-level providers, connects hospitals, clinics and medical groups with the most qualified and career-minded candidates . Our clients include academic medical centers, integrated delivery systems, multispecialty and monospecialty practices nationwide. Since 1990, Enterprise Medical Services has provided experienced staff and superior service to provide applicants and healthcare centers with a positive and successful recruiting experience.

Learn more.

Trauma surgeons

Pediatric surgeons

Breast surgeons

The ACS Surgery Career Connection is the premier resource for connecting highly qualified surgeons with the best career opportunities in the country. Find your next career opportunity. To log in today!

]]>
Cosmetic and Medical Tattoo Specialists “About Face and Body” Celebrate Ten Years of Success https://rhinoplastydigest.com/cosmetic-and-medical-tattoo-specialists-about-face-and-body-celebrate-ten-years-of-success/ Mon, 06 Jun 2022 02:05:00 +0000 https://rhinoplastydigest.com/cosmetic-and-medical-tattoo-specialists-about-face-and-body-celebrate-ten-years-of-success/ About Face and Body offers a wide range of permanent cosmetic services and recently published a blog post outlining the top ten microblading questions. ORLANDO, FLORIDA, USA, June 5, 2022 /EINPresswire.com/ — Founded in 2012 by sisters Jennifer Williams and Michelle Malquist, About face and body is pleased to announce the upcoming celebration of its […]]]>

About Face and Body offers a wide range of permanent cosmetic services and recently published a blog post outlining the top ten microblading questions.

ORLANDO, FLORIDA, USA, June 5, 2022 /EINPresswire.com/ — Founded in 2012 by sisters Jennifer Williams and Michelle Malquist, About face and body is pleased to announce the upcoming celebration of its 10th anniversary. Recognized throughout the Orlando area for their artistry, friendliness and compassion, Jennifer and Michelle have earned an excellent reputation not only with their clients, but also among plastic surgeons, many of whom refer their patients to About Face and Bodysuit for post-operative procedures. .

Trained in the latest techniques to deliver the best possible results, Jennifer and Michelle’s services include medical tattooing, such as the 3D Areola tattoo, scar revision/camouflage, and microchanneling of Procell stem cells, an anti-aging treatment that uses the body’s ability to heal itself.

According to Jennifer, one of their specialties and most requested services is microblading.

“Microblading is ideal for a client who wants to fill in areas of the natural forehead that are sparse or lack hair in certain areas,” she says. “Not everyone is a candidate for microblading, so it’s very important to choose an eyebrow artist who knows several techniques to achieve your goal.”

With ten years of experience behind them, the sisters wrote a blog post featuring the Top Ten Microblading Questions.

“If microblading is something you’ve considered in the past, you probably have a lot of questions. Our blog provides plenty of information to consider, but we also suggest you take advantage of our free pre-consultation on the face, which you can find on our website Everyone is different and we want to make sure we offer you the treatment that best suits your needs!

About Face & Body has racked up numerous 5-star reviews for microblading:

“I love my new eyebrows (Microblading), I had them done yesterday. I was a little scared at first because I had heard it was painful, but the numbing cream they used was great, I felt no pain! Very knowledgeable and took the time to explain everything. Would definitely recommend them!” – Work

For more information or to book a pre-consultation, please visit the website at https://aboutyourfaceandbody.com/.

About the company

About Face and Body is a joint partnership between two sisters, Jennifer Williams and Michelle Malquist. Both busy moms with ten children between them, they understand how hectic life can be and are on a mission to provide women with the convenient, quick solutions they need. Founded in 2012, About Face and Body offers a range of permanent cosmetic products including Tattoo Removal/Lightening, 3D Areola Tattooing, Scar Camouflage and Procell MicroCanneling.

Jennifer Williams
About face and body
+1 407-574-8383
info@afab.ink

]]>